Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27569609 | 0.98 | CHKA (0.56) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL6561470 | 0.98 | CHKA (0.59) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL31403228 | 0.93 | ALDH1A1 (0.56) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| Fluoride SCHEMBL27569600 | 0.91 | CHKA (0.53) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL31013493 | 0.91 | ALDH1A1 (0.62) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL17857889 | 0.90 | HTR1A (0.53) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL11548897 | 0.88 | ALDH1A1 (0.58) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| Fluoride SCHEMBL27569822 | 0.86 | MEN1 (0.56) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL93630 | 0.85 | L3MBTL1 (0.59) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 | |
| SCHEMBL8542780 | 0.85 | L3MBTL1 (0.59) | CHKAALDH1A1TP53HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101274932-B | 2-methyl-5- azomycin-1-(3-chloro-2-hydroxypropyl) chloro-substitutive derivate, preparation thereof and application thereof | SICHUAN BAILI PHARMACEUTICAL CO LTD | 2012-10-10 | — | — | CN | claimed |
| CN-101274932-A | 2-methyl-5- azomycin-1-(3-chloro-2-hydroxypropyl) chloro-substitutive derivate, preparation thereof and application thereof | SICHUAN BAILI PHARMACEUTICAL C (CN) | 2008-10-01 | — | — | CN | claimed |
| CN-118598798-A | Preparation method for directly synthesizing arylamine compound based on aromatic hydrocarbon and fatty amine | 沈阳药科大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| CN-112778125-B | Aryl phenol compound and synthesis method and application thereof | 华东师范大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-112341376-B | Preparation method of cycloolefine amine sulfone derivative | 温州医科大学 | 2022-12-06 | — | — | CN | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-112778125-A | Aryl phenol compound and synthesis method and application thereof | 华东师范大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-112341376-A | Preparation method of cycloolefine amine sulfone derivative | 温州医科大学 | 2021-02-09 | — | — | CN | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5817877-A | Metal-catalyzed amination of organic sulfonates to organic amines | YALE UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5489599-A | FUNGICIDES | SHELL RESEARCH LIMITED (GB) | 1996-02-06 | — | — | US | disclosed |
| WO-1992012130-A1 | PIPERIDINE DERIVATIVES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494717-A1 | Piperidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CHKA 2600/4885ALDH1A1 481/4885TP53 2420/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CHKA 2692/4885ALDH1A1 552/4885TP53 2319/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | CHKA 2600/4885ALDH1A1 481/4885TP53 2420/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CHKA 2600/4885ALDH1A1 481/4885TP53 2420/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | CHKA 3705/4885ALDH1A1 404/4885TP53 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.